[Form 4] LeMaitre Vascular, Inc. Insider Trading Activity

Rhea-AI Filing Summary

David B. Roberts, serving as President and Director of LeMaitre Vascular, acquired a series of dividend equivalent rights tied to previously granted restricted stock units and performance share units. The rights, recorded on 09/04/2025, represent the economic equivalent of shares of the issuer's common stock and arise from awards dated 12/2/2020, 12/11/2021, 12/12/2022, 12/8/2023, 12/6/2024 and 2/18/2025. The reported increments of dividend equivalent rights total 18.5799 share-equivalents across eight award lines, each showing zero purchase price and classified as direct ownership. The table lists the post-transaction beneficially owned share-equivalents for each line, indicating modest accruals that vest proportionately with the underlying awards.

Positive

• Transparency: The filing discloses accruals for dividend equivalent rights across specific award grant dates, improving clarity on executive compensation.
• Direct ownership: The dividend equivalent rights are reported as direct holdings with $0 purchase price, consistent with plan terms and transparent accounting.

Negative

• None.

Insights

Financial Analyst

TL;DR: Small accrual of dividend equivalent rights totaling 18.5799 share-equivalents; immaterial to valuation but signals routine executive compensation accruals.

The transaction consists of dividend equivalent rights credited to previously granted restricted stock units and performance share units, not open-market purchases or sales. Each line shows a fractional share-equivalent accrued with a $0 price and direct ownership. The aggregate 18.5799 share-equivalents is negligible relative to a typical market-cap equity base and therefore unlikely to move investor valuations or indicate insider confidence changes. This is a compensation accounting event reflecting vesting dynamics rather than a deliberate trading decision.

Corporate Governance Expert

TL;DR: Routine record of dividend equivalents from equity awards; consistent with standard executive pay practices and vesting schedules.

The filing documents dividend equivalent rights tied to multiple award grants across several years, each vesting proportionately with the underlying RSUs/PSUs. Reporting the accruals as direct ownership with $0 price aligns with standard plan mechanics. There are no indications of accelerated vesting, discretionary payouts, or transactions that change voting control. From a governance perspective, this is a routine disclosure of compensation-related accruals and does not raise immediate governance concerns.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Roberts David B

(Last) (First) (Middle)

C/O LEMAITRE VASCULAR, INC.

63 SECOND AVENUE

(Street)

BURLINGTON MA 01803

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LEMAITRE VASCULAR INC [ LMAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and Director

3. Date of Earliest Transaction (Month/Day/Year)
09/04/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Dividend Equivalent Rights	(1)	09/04/2025		A		0.7211		(1)	(1)	Common Stock	0.7211	$0	17.1959	D
Dividend Equivalent Rights	(2)	09/04/2025		A		1.3714		(2)	(2)	Common Stock	1.3714	$0	25.3792	D
Dividend Equivalent Rights	(3)	09/04/2025		A		2.7926		(3)	(3)	Common Stock	2.7926	$0	34.8043	D
Dividend Equivalent Rights	(4)	09/04/2025		A		2.7926		(4)	(4)	Common Stock	2.7926	$0	34.1213	D
Dividend Equivalent Rights	(5)	09/04/2025		A		3.5808		(5)	(5)	Common Stock	3.5808	$0	25.8906	D
Dividend Equivalent Rights	(6)	09/04/2025		A		4.2906		(6)	(6)	Common Stock	4.2906	$0	27.2657	D
Dividend Equivalent Rights	(7)	09/04/2025		A		2.7639		(7)	(7)	Common Stock	2.7639	$0	9.247	D
Dividend Equivalent Rights	(8)	09/04/2025		A		0.2669		(8)	(8)	Common Stock	0.2669	$0	0.8937	D

Explanation of Responses:

1. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/2/2020 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

2. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/11/2021 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

3. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/12/2022 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

4. These dividend equivalent rights accrued on a Performance Share Unit (PSU) award granted on 12/12/2022 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

5. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/8/2023 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

6. These dividend equivalent rights accrued on a Performance Share Unit (PSU) award granted on 12/8/2023 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

7. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/6/2024 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

8. These dividend equivalent rights accrued on a restricted stock unit award granted on 2/18/2025 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

	/s/ Nathan Ulrich	09/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did David B. Roberts report on Form 4 for LMAT?

He reported accruals of dividend equivalent rights tied to previously granted restricted stock units and performance share units, recorded on 09/04/2025.

How many dividend equivalent rights were acquired by the reporting person?

The reported increments total 18.5799 share-equivalents across eight award lines.

Are these purchases or open-market transactions?

No. The entries are dividend equivalent rights credited on awards with a $0 price, not open-market buys or sales.

Do these entries change control or voting power at LeMaitre Vascular (LMAT)?

The filing shows direct ownership of small fractional share-equivalents; there is no indication of a material change in control or voting power.

Which award grant dates produced these dividend equivalent rights?

Grant dates listed include 12/2/2020, 12/11/2021, 12/12/2022, 12/8/2023, 12/6/2024 and 2/18/2025, with rights vesting proportionately with each award.

What is the economic meaning of a dividend equivalent right in this filing?

Each dividend equivalent right is described as the economic equivalent of one share of the issuer's common stock and accrues to the reporting person based on award terms.